Pharma Sessions

The episode contains a handful of genuinely valuable observations - particularly the audited chemotherapy uptake data and the reading-level finding - but large portions are consumed by karaoke small talk, a sponsor read, host self-anecdotes, and meandering pleasantries that dilute the signal considerably.

“just because something's published in the New England Journal of Medicine doesn't mean it's going to make it into the clinic, even my own clinics”

“we did a UK audit and it was 27%”

The concrete chemotherapy-uptake audit story is a nice first-person illustration of a real problem, and the framing of 'do no harm' as a professional hiding mechanism is modestly contrarian, but the broader themes - knowledge translation gaps, democratising medicine, misinformation bad - are well-worn in health-policy and med-ed circles with little genuinely novel structuring.

“The maxim of do no harm is something that we probably hide behind a little bit”

“There's no randomized trial showing that robotic surgery is better than open surgery. But I think they showed that with an energy and an education program, they were able to do that”

Dr. Chowdhury is a credible, genuine practitioner - head of a GU oncology department, MRC role, trained at Dana Farber - who has actually done the clinical work he describes; however, he is now primarily pitching a nascent startup and the interview leans into founder-storytelling rather than deep practitioner expertise.

“I was the head of the GU uh department there”

“I have a role at the Medical Research Council in the UK”

A few strong concrete data points anchor the episode - the 27% actual vs. 70-80% perceived chemotherapy uptake gap, the sub-10 reading-age finding, a named Janssen contact and a specific date - but descriptions of Open Medicine's traction, user base, and differentiation remain entirely aspirational and unquantified.

“we did a UK audit and it was 27%”

“Almost half the people coming had a reading age less than 10. A lot of people couldn't read”

The host is affable but consistently defers, fills significant airtime with his own anecdotes and personal asides, opens with an extended karaoke icebreaker, and never challenges the guest's claims about Open Medicine's differentiation, business model, or likelihood of adoption - resulting in a comfortable PR conversation rather than a probing interview.

“what is your go-to or go-to's for karaoke when you're forced to perform?”

“Is your take that this simplification of taking the Uber expert in a field and putting their evidence-based guidelines essentially into this format is solving the access problem via faster access, more complete access?”